Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Influence of cannabidiol on delta-9-tetrahydrocannabinol effects.

Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB.

Clin Pharmacol Ther. 1976 Mar;19(3):300-9.

PMID:
770048
2.

Clinical studies on the interaction of psychopharmacologic agents with marihuana.

Lemberger L, Dalton B, Martz R, Rodda B, Forney R.

Ann N Y Acad Sci. 1976;281:219-28. Review. No abstract available.

PMID:
798524
3.
4.

The combined effect of marihuana and dextroamphetamine.

Forney R, Martz R, Lemberger L, Rodda B.

Ann N Y Acad Sci. 1976;281:162-70. Review.

PMID:
798521
5.

Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.

Martin-Santos R, Crippa JA, Batalla A, Bhattacharyya S, Atakan Z, Borgwardt S, Allen P, Seal M, Langohr K, Farré M, Zuardi AW, McGuire PK.

Curr Pharm Des. 2012;18(32):4966-79. Review.

PMID:
22716148
6.

Cannabis, cannabidiol, and epilepsy--from receptors to clinical response.

Szaflarski JP, Bebin EM.

Epilepsy Behav. 2014 Dec;41:277-82. doi: 10.1016/j.yebeh.2014.08.135. Epub 2014 Oct 1. Review.

PMID:
25282526
7.

The relationship between cannabidiol and psychosis: A review.

Silva TB, Balbino CQ, Weiber AF.

Ann Clin Psychiatry. 2015 May;27(2):134-41. Review.

PMID:
25954940
8.

A systematic review of the antipsychotic properties of cannabidiol in humans.

Iseger TA, Bossong MG.

Schizophr Res. 2015 Mar;162(1-3):153-61. doi: 10.1016/j.schres.2015.01.033. Epub 2015 Feb 7. Review.

PMID:
25667194
9.

Does Cannabidiol Protect Against Adverse Psychological Effects of THC?

Niesink RJ, van Laar MW.

Front Psychiatry. 2013 Oct 16;4:130. doi: 10.3389/fpsyt.2013.00130. Review.

10.

Delta(9) -tetrahydrocannabinol and cannabidiol as potential curative agents for cancer: A critical examination of the preclinical literature.

Fowler CJ.

Clin Pharmacol Ther. 2015 Jun;97(6):587-96. doi: 10.1002/cpt.84. Epub 2015 May 2. Review.

PMID:
25669486
11.

Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents.

Fasinu PS, Phillips S, ElSohly MA, Walker LA.

Pharmacotherapy. 2016 Jul;36(7):781-96. doi: 10.1002/phar.1780. Review.

PMID:
27285147
12.

Safety and side effects of cannabidiol, a Cannabis sativa constituent.

Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA.

Curr Drug Saf. 2011 Sep 1;6(4):237-49. Review.

PMID:
22129319
13.

A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.

Zuardi AW, Crippa JA, Hallak JE, Bhattacharyya S, Atakan Z, Martin-Santos R, McGuire PK, Guimarães FS.

Curr Pharm Des. 2012;18(32):5131-40. Review.

PMID:
22716160
14.

Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.

Burstein S.

Bioorg Med Chem. 2015 Apr 1;23(7):1377-85. doi: 10.1016/j.bmc.2015.01.059. Epub 2015 Feb 7. Review.

PMID:
25703248
15.

Cannabidiol in medical marijuana: Research vistas and potential opportunities.

Rong C, Lee Y, Carmona NE, Cha DS, Ragguett RM, Rosenblat JD, Mansur RB, Ho RC, McIntyre RS.

Pharmacol Res. 2017 May 10;121:213-218. doi: 10.1016/j.phrs.2017.05.005. [Epub ahead of print] Review.

PMID:
28501518
16.
17.

In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease.

Watt G, Karl T.

Front Pharmacol. 2017 Feb 3;8:20. doi: 10.3389/fphar.2017.00020. eCollection 2017. Review.

18.

Neuronal and molecular effects of cannabidiol on the mesolimbic dopamine system: Implications for novel schizophrenia treatments.

Renard J, Norris C, Rushlow W, Laviolette SR.

Neurosci Biobehav Rev. 2017 Apr;75:157-165. doi: 10.1016/j.neubiorev.2017.02.006. Epub 2017 Feb 7. Review.

PMID:
28185872
19.

Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence.

Rohleder C, Müller JK, Lange B, Leweke FM.

Front Pharmacol. 2016 Nov 8;7:422. eCollection 2016. Review.

20.

The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law.

Mead A.

Epilepsy Behav. 2017 Feb 3. pii: S1525-5050(16)30585-6. doi: 10.1016/j.yebeh.2016.11.021. [Epub ahead of print] Review.

Supplemental Content

Support Center